Abstract:Background 5q‐Spinal muscular atrophy (SMA) is now one of the 5% treatable rare diseases worldwide. As disease‐modifying therapies alter disease progression and patient phenotypes, paediatricians and consulting disciplines face new unknowns in their treatment decisions. Conclusions made from historical patient data sets are now mostly limited, and new approaches are needed to ensure our continued best standard‐of‐care practices for this exceptional patient group. Here, we present a data‐driven machine learning approach to a rare disease data set to predict spinal muscular atrophy (SMA)‐associated scoliosis. Methods We collected data from 84 genetically confirmed 5q‐SMA patients who have received novel SMA therapies. We performed expert domain knowledge‐directed feature engineering, correlation and predictive power score (PPS) analyses for feature selection. To test the predictive performance of the selected features, we trained a Random Forest Classifier and evaluated model performance using standard metrics. Results The SMA data set consisted of 1304 visits and over 360 variables. We performed feature engineering for variables related to 'interventions', 'devices', 'orthosis', 'ventilation', 'muscle contractures' and 'motor milestones'. Through correlation and PPS analysis paired with expert domain knowledge feature selection, we identified relevant features for scoliosis prediction in SMA that included disease progression markers: Hammersmith Functional Motor Scale Expanded 'HFMSE' (PPS = 0.27) and 6‐Minute Walk Test '6MWT' scores (PPS = 0.44), 'age' (PPS = 0.41) and 'weight' (PPS = 0.49), 'contractures' (PPS = 0.17), the use of 'assistive devices' (PPS = 0.39, 'ventilation' (PPS = 0.16) and the presence of 'gastric tubes' (PPS = 0.35) in SMA patients. These features were validated using expert domain knowledge and used to train a Random Forest Classifier with an observed accuracy of 0.82 and an average receiver operating characteristic (ROC) area of 0.87. Conclusion The introduction of disease‐modifying SMA therapies, followed by the implementation of SMA in newborn screenings, has presented physicians with never‐seen patients. We used feature engineering tools to overcome one of the main challenges when using data‐driven approaches in rare disease data sets. Through predictive modelling of this data, we defined disease progression markers, which are easily assessed during patient visits and can help anticipate scoliosis onset. This highlights the importance of progressive features in the drug‐induced revolution of this rare disease and further supports the ongoing efforts to update the SMA classification. We advocate for the consistent documentation of relevant progression markers, which will serve as a basis for data‐driven models that physicians can use to update their best standard‐of‐care practices.

Machine learning-enhanced electrical impedance myography to diagnose and track spinal muscular atrophy progression

Functional Mixed-Effects Modeling of Longitudinal Duchenne Muscular Dystrophy Electrical Impedance Myography Data Using State-Space Approach

Non-Invasive Muscular Atrophy Causes Evaluation for Limb Fracture Based on Flexible Surface Electromyography System

From data to discovery: AI-guided analysis of disease-relevant molecules in spinal muscular atrophy (SMA)

Distinguishing normal, neuropathic and myopathic EMG with an automated machine learning approach

An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies

Detection of survival motor neuron protein in buccal cells through electrochemiluminescence-based assay

Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples

Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

Update on Biomarkers in Spinal Muscular Atrophy

Deep Learning of Ultrasound Imaging for Evaluating Ambulatory Function of Individuals with Duchenne Muscular Dystrophy

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

At-home wearables and machine learning capture motor impairment and progression in adult ataxias

The significance of machine learning in neonatal screening for inherited metabolic diseases

Feature Engineering for the Prediction of Scoliosis in 5q‐Spinal Muscular Atrophy

AML-DECODER: Advanced Machine Learning for HD-sEMG Signal Classification—Decoding Lateral Epicondylitis in Forearm Muscles

A novel evaluation method of survival motor neuron protein as a biomarker of spinal muscular atrophy by imaging flow cytometry

Development of an ultrasound‐based metric of muscle functional capacity for use in patients with neuromuscular disease

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?

Muscle Electrical Impedance Analysis Based on Blind Source Separation